id: NEW:medications_for_alcohol_use_disorder_maud_to_all_cause_mortality_rate
name: Medications for Alcohol Use Disorder (MAUD) â†’ All-Cause Mortality Rate
from_node:
  node_id: NEW:medications_for_alcohol_use_disorder_maud
  node_name: Medications for Alcohol Use Disorder (MAUD)
to_node:
  node_id: all_cause_mortality_rate
  node_name: All-Cause Mortality Rate
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Patients with alcohol use disorder and alcohol-associated cirrhosis are
  prescribed medications for alcohol use disorder (acamprosate or naltrexone)'
- 'Step 2: MAUD helps patients achieve and maintain abstinence from alcohol, reducing
  ongoing liver damage and alcohol-related complications'
- 'Step 3: Reduced alcohol consumption decreases further hepatic injury, slows cirrhosis
  progression, and prevents decompensation events'
- 'Step 4: Improved liver function and reduced alcohol-related systemic effects lead
  to decreased all-cause mortality (HR 0.80)'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: A. Rabiee et al. 2023. Medications for alcohol use disorder improve
    survival in patients with hazardous drinking and alcohol-associated cirrhosis.
    Hepatology Communications.
  supporting_citations: []
description: Medications for alcohol use disorder (acamprosate and naltrexone) are
  associated with a 20% reduction in all-cause mortality among patients with alcohol-associated
  cirrhosis and high-risk alcohol use behavior. This protective effect operates through
  improved abstinence rates, which reduces ongoing hepatic injury and prevents further
  cirrhosis progression. Despite their effectiveness, MAUD remain underutilized in
  this population, with only 9.7% of eligible patients receiving these medications.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.8
    type: hazard_ratio
    ci_lower: 0.67
    ci_upper: 0.97
  p_value: 0.024
  sample_size: 9131
moderators:
- name: Duration of MAUD exposure
  direction: strengthens
  strength: moderate
  description: 39% of patients had MAUD exposure >3 months; longer exposure duration
    may improve outcomes
- name: Cirrhosis decompensation history
  direction: weakens
  strength: moderate
  description: History of cirrhosis decompensation was the strongest negative predictor
    of MAUD prescription, suggesting underutilization in sicker patients
- name: Concurrent depression diagnosis
  direction: strengthens
  strength: weak
  description: Concurrent depression diagnosis was a positive predictor of MAUD prescription,
    potentially reflecting better mental health service engagement
